Literature DB >> 16108294

"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.

Debora A Paterniti1, Joy Melnikow, Jim Nuovo, Stuart Henderson, Michael DeGregorio, Miriam Kuppermann, Robert Nease.   

Abstract

OBJECTIVE: To investigate how ethnically diverse women who are eligible for tamoxifen prophylaxis because of their breast cancer risk decide about tamoxifen use for risk reduction.
DESIGN: A qualitative intervention pilot study used focus groups to discuss the use of tamoxifen and to identify the concerns of ethnically diverse women about the preventive use of this drug. Focus group discussion involved exploration of the benefits and risks of tamoxifen prophylaxis, presentation of a standardized educational intervention, and focused discussion on attitudes about tamoxifen for prevention. Prominent themes emerged from iterative review of focus group transcripts.
RESULTS: Fear of breast cancer was not prominent, and participants were less inclined to take tamoxifen as preventive therapy after receiving information. Decisions were based on participants' understandings of competing risks and benefits. Specifically, participants expressed limited willingness to take medication with potential serious side effects for risk reduction and were unwilling to discontinue hormone replacement therapy. Uneasiness about the reliability of scientific studies surfaced in the focus groups comprised of White and Latina women. African-American women described faith as important to prevention.
CONCLUSIONS: Women were wary of taking a drug for a disease they might not develop. Women felt they had options other than tamoxifen to reduce their risk of breast cancer, including early detection, diet, faith, and complementary and alternative therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108294

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  11 in total

Review 1.  Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  Mary E Ropka; Jess Keim; John T Philbrick
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).

Authors:  Christine Holmberg; Erika A Waters; Katie Whitehouse; Mary Daly; Worta McCaskill-Stevens
Journal:  Med Decis Making       Date:  2015-07-16       Impact factor: 2.583

3.  Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

Authors:  Erika A Waters; Timothy S McNeel; Worta McCaskill Stevens; Andrew N Freedman
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

4.  Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

Authors:  Erika A Waters; Kathleen A Cronin; Barry I Graubard; Paul K Han; Andrew N Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

5.  African American women's perspectives on breast cancer: implications for communicating risk of basal-like breast cancer.

Authors:  Marlyn Allicock; Neasha Graves; Kathleen Gray; Melissa A Troester
Journal:  J Health Care Poor Underserved       Date:  2013-05

6.  Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.

Authors:  Ida J Korfage; Andrea Fuhrel-Forbis; Peter A Ubel; Brian J Zikmund-Fisher; Sarah M Greene; Jennifer B McClure; Dylan M Smith; Sharon Hensley Alford; Angela Fagerlin
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

Review 7.  Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.

Authors:  Andrea DeCensi; Mangesh A Thorat; Bernardo Bonanni; Samuel G Smith; Jack Cuzick
Journal:  Ecancermedicalscience       Date:  2015-11-24

8.  Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.

Authors:  Lindsey C Karavites; Subhashini Allu; Seema A Khan; Karen Kaiser
Journal:  BMC Cancer       Date:  2015-11-09       Impact factor: 4.430

Review 9.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  S G Smith; I Sestak; A Forster; A Partridge; L Side; M S Wolf; R Horne; J Wardle; J Cuzick
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976

Review 10.  Physician and Patient Barriers to Breast Cancer Preventive Therapy.

Authors:  Susan Hum; Melinda Wu; Sandhya Pruthi; Ruth Heisey
Journal:  Curr Breast Cancer Rep       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.